scholarly journals Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer

2021 ◽  
Author(s):  
Binhao Huang ◽  
Maria Christine Xu ◽  
Arjun Pennathur ◽  
Zhigang Li ◽  
Zhiguo Liu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Squamous Cell ◽  
Adjuvant Treatment ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
R0 Resection ◽  
Muscularis Mucosa

Abstract Objective To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. Methods We evaluated the outcomes of 46 esophageal squamous cell cancer (ESCC) patients with T1aM3-T1b stage who underwent ER + AT from the Esophageal Cancer Endoscopic Therapy Consortium (ECETC) and compared these outcomes to 92 patients who underwent esophagectomy. Propensity score matching (1:2) was used, with overall survival (OS) and relapse-free survival (RFS) being compared between the two groups. Results During a median follow-up of 32 months, there were no statistical differences (P = 0.226) in OS between the two groups. The 1-, 2-, and 3-year overall survival in the esophagectomy group was 95%, 91%, and 84%, respectively. There were no mortalities within three years in the ER + AT group. The RFS between the two groups was also not significantly different (P = 0.938). The 1-, 2-, and 3-year RFS of patients in the esophagectomy group was 90%, 90%, and 83%, respectively, while it was 97%, 94%, and 74% in the ER + AT group, respectively. The local recurrence rates between the two groups were not significantly different (P = 0.277). Conclusions This first multicenter analysis showed similar outcomes were found regarding OS and RFS between the two groups in T1aM3-T1b stage patients. ER + AT may be considered in high-risk patients or for those who refuse esophagectomy.

PS01.145: SIMULTANEOUS RESECTION FOR ESOPHAGEAL CANCERS WITH MULTIPLE PRIMARY CANCERS

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 90-91
Author(s):  
Atsushi Takeno ◽  
Toru Masuzawa ◽  
Kohei Murakami ◽  
Kenji Kawai ◽  
Takuya Sakamoto ◽  
...  
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Conflicts Of Interest ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Multiple Primary Cancers ◽  
Simultaneous Surgery ◽  
Multiple Primary

Abstract Background Esophageal cancer is frequently associated with multiple primary cancers and they are sometimes found simultaneously. The aim of this retrospective study was to clarify the clinical outcome of simultaneous surgery for patients with esophageal squamous cell cancer with multiple primary cancers. Methods Clinicopathologic features and surgical outcomes were compared between 14 simultaneous resections (SR group) and 108 single esophagectomy (E group) among 122 patients who underwent esophagectomy for esophageal squamous cell cancer in 2005–2013. Results The most common site of multiple primary cancers was the stomach (6 patients; 43%), followed by the stomach (5 patients; 36%), the lung (4 patients; 29%), the tongue, the colon, and the duodenum (1 patient; 7%). The number of multiple primary cancers was double (12 patients; 86%), triple (1 patient; 7%), and quadruple (1 patient; 7%). The incidence of antecedent and subsequent cancers didn’t differ between two groups. The SR group increased blood loss and prolonged operation time. However, there were no differences in postoperative morbidity, mortality and hospital days between the two groups. The SR group had shorter overall survival than the E group (3 years MST 54% vs 74%, Log rank P = 0.056) Conclusion The presence of synchronous cancers complicates the surgical resection of esophageal cancer. Although simultaneous surgery for patients with esophageal squamous cell cancer with multiple primary cancers was found to be comparably safe, the overall survival was poor than the single esophagectomy group. Treatment strategy condidering multidisciplinary approach is needed to improve the survival. Disclosure All authors have declared no conflicts of interest.

scholarly journals Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu-Chieh Ho ◽  
Yuan-Chun Lai ◽  
Hsuan-Yu Lin ◽  
Ming-Hui Ko ◽  
Sheng-Hung Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Performance Status ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Lymphocyte Ratio ◽  
Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

Risk Patterns of Subsequent Primary Cancers following Esophagectomy in Early-Stage Thoracic Esophageal Squamous Cell Cancer Patients

2015 ◽  
Vol 101 (3) ◽  
pp. 328-333 ◽  
Author(s):  
Wen-Si Hu ◽  
Zeng-Jun Liu ◽  
Jian-Bo Zhang ◽  
Zeng-Liang Wang ◽  
Ning Yang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer

Endoscopic resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage II or III esophageal squamous cell cancer.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 109-109
Author(s):  
Makomo Makazu ◽  
Ken Kato ◽  
Hajime Takisawa ◽  
Shigetaka Yoshinaga ◽  
Ichiro Oda ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Survival Rate ◽  
Endoscopic Resection ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Residual Tumor ◽  
Local Failure ◽  
Esophageal Squamous Cell Cancer ◽  
Stage Ii

109 Background: Local failure after definitive chemotherapy and/or radiotherapy for stage II or III esophageal cancer is one of the causes of poor outcome. Endoscopic resection (ER) is an effective treatment for superficial esophageal cancer. However, its curative potential and safety remain unclear for local recurrent or residual tumor. Methods: Two hundred and sixty patients (pts.) who received definitive chemotherapy and/or radiotherapy for stage II or III esophageal squamous cell cancer between January 2000 and July 2007 were retrospectively reviewed. Results: Characteristics of all patients were as follows: median age of 65 (range 35-86); male/female: 226/34; performance status 0/1/2:117/141/2; clinical stage IIA/IIB/III: 64/70/126; regimen of chemoradiotherapy/radiotherapy: 235/15; and radiation dose 50.4/60/>66 Gy: 31/218/10. Of 260pts, 170 (65%) achieved complete response after chemoradiotherapy. Median survival time was 38.5 months and 5-year survival rate was 43.5%. While 81 of them had recurrent disease, 39 had locoregional recurrence without distant metastasis. While 86 of 260 pts (33%) had residual disease after chemoradiotherapy, 68 had only locoregional disease. Of the 107 pts who had only locoregional recurrent or residual tumor, 15 (14%) underwent salvage ER (17 lesions in total). Tumor depth was limited in mucosal layer in 10 lesions and submucosal in 7 lesions. En bloc resection was performed in 9 lesions (52.9%). The vertical margin was free from cancer cells in 15 lesions (88.2%). No major complications, such as hemorrhage requiring blood transfusion and perforation, were experienced. Only one pt experienced minor hemorrhage 16 days after EMR, and was treated by endoscopic treatment. At a median follow-up period of 40.0 months (range, 0.7-94 months) after salvage ER, no recurrence was detected in 9 pts. (60%). Local recurrence was detected in 4 pts. (27%). The clinical courses of the remaining 2 pts were unknown. Three-year survival rate after salvage ER was 58%. Conclusions: Salvage ER is feasible and one of the promising treatments for local recurrent or residual esophageal cancer after chemoradiotherapy or radiotherapy.

Topical oro-dispersible budesonide tablets for stricture prevention after near circumferential ESD for esophageal squamous cell cancer – a case report

2021 ◽  
Author(s):  
Daniel Mathies ◽  
Tsuneo Oyama ◽  
Ingo Steinbrück ◽  
Franz Ludwig Dumoulin
Keyword(s):  
Case Report ◽  
High Risk ◽  
Endoscopic Resection ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Complete Healing ◽  
Esophageal Squamous Cell Cancer ◽  
Stricture Formation ◽  
Local Injections

Abstract Background Endoscopic resection is the treatment of choice for early esophageal cancers. However, resections comprising more than 70–80 % of the circumference are associated with a high risk of stricture formation. Currently, repetitive local injections and/or systemic steroids are given for prevention. Case report We present here the case of a 78-year-old male patient who had a near circumferential endoscopic submucosal dissection for a pT1a mm, L0, V0, R0, G2 esophageal squamous cell cancer. At the end of endoscopic resection, 80 mg of triamcinolone was injected locally. The patient was then treated with oro-dispersible budesonide tablets (2 × 1 mg/day) and nystatin (4 × 100 000 I.E.) for 8 weeks. This treatment resulted in complete healing without any stricture formation and did not result in any complications. Discussion Treatment with orodispersible budesonide tablets could help prevent strictures after large endoscopic resections in the esophagus.

Randomized, Placebo-Controlled, Esophageal Squamous Cell Cancer Chemoprevention Trial of Selenomethionine and Celecoxib

2005 ◽  
Vol 129 (3) ◽  
pp. 863-873 ◽  
Author(s):  
Paul J. Limburg ◽  
Wenqiang Wei ◽  
Dennis J. Ahnen ◽  
Youlin Qiao ◽  
Ernest T. Hawk ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Cancer Chemoprevention ◽  
Esophageal Squamous Cell Cancer ◽  
Chemoprevention Trial
Sign in / Sign up

Export Citation Format

Share Document